Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2017
Reporting Period: The filing references financial results for the quarterly period ended June 30, 2017, announced via a press release attached as Exhibit 99.1. The filing itself primarily reports on corporate governance changes effective August 9, 2017.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
Board Appointment: The Board of Directors appointed Gwen A. Melincoff as a Class III director, effective immediately. Her initial term expires at the 2018 annual meeting of shareholders.
Compensation Grant: Ms. Melincoff was granted an option to purchase shares of common stock with a fair market value of $185,000. This option vests and becomes exercisable on August 9, 2018, subject to continued service.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights Ms. Melincoff's extensive background, including over 25 years of leadership in biotechnology and pharmaceuticals, with prior roles at BTG International Inc. and Shire Plc.
Risks and Contingencies: The filing states there are no related party transactions involving Ms. Melincoff reportable under Item 404(a) of Regulation S-K and no arrangements regarding her selection as a director. No specific financial risks or outlook guidance are detailed in the text provided.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2017 financial results, as the 8-K text does not list numerical data.
- Verify the vesting schedule and terms of the $185,000 stock option granted to the new director.
- Confirm the impact of the new board member on the company's strategic direction given her background in business development and venture capital.
- Check the Definitive Proxy Statement on Schedule 14A (filed April 13, 2017) for details on the standard annual compensation for non-employee directors.